Exogenous Growth Hormone Recommended Over AOD-9604 for Fat Loss
The speaker recommends replacing AOD-9604 with regular exogenous growth hormone, arguing it provides equal or greater benefit for body composition and lipolysis. No specific dosage protocol is provided in this excerpt. The recommendation is framed as a superior alternative given AOD-9604's failed clinical trial record.
AOD-9604 Mechanism: Isolated Lipolytic Fragment of Growth Hormone
AOD-9604 was designed by isolating the portion of the growth hormone molecule responsible for lipolysis (fat breakdown). The intent was to capture the body composition benefits of growth hormone without its other systemic effects.
AOD-9604 Primary Mechanism: Fat Mobilization
The speaker identifies fat mobilization as the core mechanism and therapeutic purpose of AOD-9604, regardless of delivery route. This is presented as the consistent outcome whether the peptide is administered via injection or buccal troché. No specific mechanistic detail (e.g., beta-3 adrenergic receptor interaction or lipolysis pathway) is elaborated upon in this transcript.
AOD-9604 Buccal Troché Dose: 500–600 mcg to Compensate for Lower Bioavailability
Because buccal/sublingual absorption is less direct than subcutaneous injection, the speaker's clinic uses a higher dose of 500–600 micrograms in the troché formulation compared to the 250 mcg injectable standard. The speaker states that doubling the dose results in effective absorption equivalent to what is therapeutically needed. No pharmacokinetic data or bioavailability studies are cited to support this dose-adjustment rationale.
Sublingual/Buccal AOD-9604 Troché as Alternative Delivery Route
The speaker's clinic transitioned most patients from injectable AOD-9604 to a compounded troché (lozenge) formulation that dissolves under the tongue or in the buccal mucosa (inner cheek). Absorption occurs through the buccal mucosa, bypassing the need for subcutaneous injection entirely. The speaker reports the results with this delivery method as 'incredible,' eliminating both the stability and lipohypertrophy issues associated with injections.
Standard Injectable AOD-9604 Dose: 250 mcg
The speaker references 250 micrograms as the standard dose for injectable AOD-9604. This figure is used as a baseline comparison point when discussing the higher doses required for the sublingual/buccal troché formulation. No specific injection frequency per dose is elaborated beyond the daily or twice-daily protocol mentioned elsewhere.
AOD-9604 Injection Protocol Requires Daily or Twice-Daily Dosing for 3–4 Months
The standard injectable AOD-9604 protocol as described by the speaker involves daily injections, sometimes administered twice per day, over a cycle duration of three to four months. This extended, high-frequency injection schedule is presented as a key reason why lipohypertrophy becomes a significant practical problem. The speaker frames this dosing frequency as an inherent design flaw of the injectable route for this peptide.
Repeated Subcutaneous Injection of AOD-9604 Causes Lipohypertrophy
Daily subcutaneous injections of AOD-9604 into the same tissue sites leads to lipohypertrophy — thickened, rubbery pockets of scar tissue under the skin. The speaker identifies this as a clinically recognized medical condition. As lipohypertrophy develops, absorption of the peptide from those injection sites worsens progressively over time.
Injectable AOD-9604 Stability Degradation in Vial
The speaker claims injectable AOD-9604 has a stability problem where the peptide gels up inside the vial over time, resulting in cloudy and thickened liquid. This physical degradation makes the solution difficult to draw properly into a syringe. The practical consequence is that the administered dose is unreliable and likely lower than intended.
AOD-9604 Failure Mode: Ineffectiveness Without Lifestyle Modification
The speaker identifies a common reason for AOD-9604 failure: users taking the peptide without making any accompanying lifestyle changes. The peptide is explicitly stated to be incapable of producing results on its own, and the burden of creating the conditions for fat oxidation remains with the user.
AOD-9604 Stacking with GLP-1 Medications for Enhanced Fat Loss
The speaker recommends combining AOD-9604 with GLP-1 receptor agonist medications as a stacking strategy. GLP-1 agents are used to create the necessary calorie deficit and appetite suppression that AOD-9604 itself does not provide. This combination is presented as the preferred approach over fasting alone.
AOD-9604 Protocol Step 3: Zone 2 Cardio Post-Injection to Burn Released Fat
The third protocol step involves performing Zone 2 cardiovascular exercise after AOD-9604 injections to oxidize the fat that the peptide has released into circulation. Recommended activities include walking and easy cycling. The timing is specifically post-injection to capitalize on the mobilized free fatty acids.
AOD-9604 Protocol Step 2: Inject During Fasting Windows with Low Insulin
AOD-9604 injections should be timed during fasting windows to maximize efficacy. The rationale given is that low insulin levels are necessary for fatty acid mobilization to convert to actual fat burning. Elevated insulin is implied to blunt the peptide's fat-releasing effect.
AOD-9604 Protocol Step 1: Calorie Deficit via GLP-1 or Fasting
The first step of the AOD-9604 fat loss protocol requires creating a calorie deficit to ensure mobilized fat is actually burned rather than re-stored. The speaker recommends using GLP-1 medications, therapeutic fasting, or ideally both in combination to achieve this deficit.
AOD-9604 Mechanism: Fat Mobilization Only (Not Burning)
AOD-9604 is described as a peptide that exclusively mobilizes fat by unlocking fat stores and releasing them into the bloodstream. It does not burn fat, suppress appetite, or boost metabolism on its own. If the mobilized fat is not subsequently burned through activity or caloric deficit, it returns to storage.
Low Insulin as a Prerequisite for AOD-9604 Fat-Burning Conversion
The speaker identifies low circulating insulin as the key physiological condition that allows AOD-9604-driven fat mobilization to result in actual fat oxidation. By implication, injecting in a fed or hyperinsulinemic state would blunt the peptide's utility. This is presented as mechanistic reasoning without citation of specific studies.
Injection Timing Protocol: Administer AOD-9604 During Fasting Window
The speaker provides a specific timing recommendation: inject AOD-9604 during a fasting window when circulating insulin levels are low. The rationale is that low insulin is a prerequisite for fat mobilization to translate into actual fat oxidation. No specific injection dose, volume, or frequency is mentioned.
Stacking Recommendation: AOD-9604 Combined with Therapeutic Fasting
Therapeutic or intermittent fasting is presented as a second strategy to pair with AOD-9604, creating the low-insulin, energy-deficit environment needed for mobilized fat to be oxidized rather than re-stored. No specific fasting protocols (e.g., 16:8, 24-hour) or durations are specified.
Stacking Recommendation: AOD-9604 Combined with GLP-1 Medications
The speaker recommends stacking AOD-9604 with GLP-1 receptor agonist medications (e.g., semaglutide, tirzepatide — though specific agents are not named) as one strategy to create the caloric deficit needed to convert fat mobilization into net fat loss. No dosages, ratios, or safety considerations for this combination are discussed.
Protocol Recommendation: Pair AOD-9604 with a Caloric Deficit for Efficacy
The speaker's core protocol recommendation is that AOD-9604 must be combined with a caloric deficit to produce meaningful fat loss results. Without an energy deficit, mobilized fatty acids are reportedly re-esterified and stored back in adipose tissue. No specific caloric targets or deficit magnitudes are provided.
AOD-9604 Has No Effect on Appetite or Metabolism
The speaker explicitly states that AOD-9604 does not suppress appetite and does not boost metabolic rate. Its sole claimed utility is increasing the availability of mobilized fat for use as fuel. This distinguishes it mechanistically from GLP-1 receptor agonists and other weight-loss agents.
AOD-9604 Mechanism: Fat Mobilizer, Not Fat Burner
The speaker describes AOD-9604's primary mechanism as fat mobilization — releasing stored fat into the bloodstream — rather than directly oxidizing or burning fat. The analogy used is 'opening a vault of cash': the fat is freed from storage but must be actively utilized or it will be re-deposited. No dosage information is provided.
Medical Supervision Required for Peptide + GLP-1 Stacking
The speaker explicitly states that stacking fat-loss peptides with GLP-1 agonists should be done 'under medical supervision.' This is the only safety caveat offered in the video. No specific contraindications, side effects, or patient screening criteria are discussed.
Stacking Fat-Loss Peptides With GLP-1 Agonists to Break Plateaus
The speaker recommends stacking one or two fat-loss peptides (AOD-9604, MOTS-c, and/or 'loop 332') alongside GLP-1 medications to address multiple metabolic systems simultaneously and break weight-loss plateaus. No specific stacking protocols, dosages, timing, or cycling guidance is provided. This is presented as a general clinical framework, not backed by cited trials.
AOD-9604 Mobilizes Stubborn Fat Without Affecting Appetite or Blood Sugar
AOD-9604 is described as a fragment of growth hormone that specifically targets stubborn fat mobilization. The speaker claims it unlocks fat stores without impacting appetite or blood sugar levels, making it complementary to GLP-1 therapy. No dosages or study citations are provided.
Introduce Peptides Throughout GLP-1 Program, Not Just at End
When asked whether to introduce new peptides after lowering a GLP-1 dose, Dr. Jones states he would be introducing peptides throughout the entire program — starting from the beginning with fat-mobilizing peptides like AOD-9604, rather than waiting until later stages.
Stacking AOD-9604 with Cagrilintide is Possible but Not Preferred
When asked whether AOD-9604 and cagrilintide can be combined, Dr. Jones confirms it is possible but expresses a preference for other GLP-1 options over cagrilintide ('Kaggy'). He frames this as theoretically acceptable but not his first-choice protocol.
AOD-9604 as a Fat-Mobilizing Peptide to Stack with GLP-1s
Dr. Jones recommends introducing a fat-mobilizing peptide like AOD-9604 at the beginning of a GLP-1 program. He categorizes AOD as a 'fat mobilizing peptide' and suggests stacking it with GLP-1 medications from the start of treatment rather than waiting until later.